85 related articles for article (PubMed ID: 10780313)
1. Use of the PFA-100 apparatus to assess platelet function in patients undergoing PTCA during and after infusion of c7E3 Fab in the presence of other antiplatelet agents.
Hézard N; Metz D; Nazeyrollas P; Droulle C; Elaerts J; Potron G; Nguyen P
Thromb Haemost; 2000 Apr; 83(4):540-4. PubMed ID: 10780313
[TBL] [Abstract][Full Text] [Related]
2. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors.
Kleiman NS; Raizner AE; Jordan R; Wang AL; Norton D; Mace KF; Joshi A; Coller BS; Weisman HF
J Am Coll Cardiol; 1995 Dec; 26(7):1665-71. PubMed ID: 7594101
[TBL] [Abstract][Full Text] [Related]
3. The effect of antiplatelet drugs, heparin, and preanalytical variables on platelet function detected by the platelet function analyzer (PFA-100).
Kottke-Marchant K; Powers JB; Brooks L; Kundu S; Christie DJ
Clin Appl Thromb Hemost; 1999 Apr; 5(2):122-30. PubMed ID: 10725993
[TBL] [Abstract][Full Text] [Related]
4. c7E3 Fab inhibits low shear flow modulated platelet adhesion to endothelium and surface-absorbed fibrinogen by blocking platelet GP IIb/IIIa as well as endothelial vitronectin receptor--results from patients with acute myocardial infarction and healthy controls.
Reininger AJ; Agneskirchner J; Bode PA; Spannagl M; Wurzinger LJ
Thromb Haemost; 2000 Feb; 83(2):217-23. PubMed ID: 10739376
[TBL] [Abstract][Full Text] [Related]
5. Shear-induced platelet aggregation is inhibited by in vivo infusion of an anti-glycoprotein IIb/IIIa antibody fragment, c7E3 Fab, in patients undergoing coronary angioplasty.
Konstantopoulos K; Kamat SG; Schafer AI; Bañez EI; Jordan R; Kleiman NS; Hellums JD
Circulation; 1995 Mar; 91(5):1427-31. PubMed ID: 7867183
[TBL] [Abstract][Full Text] [Related]
6. Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention.
Madan M; Berkowitz SD; Christie DJ; Jennings LK; Smit AC; Sigmon KN; Glazer S; Tcheng JE
Am Heart J; 2001 Feb; 141(2):226-33. PubMed ID: 11174336
[TBL] [Abstract][Full Text] [Related]
7. Early and late clinical outcome following coronary angioplasty performed with platelet glycoprotein IIb/IIIa receptor inhibition: the EPIC Trial results.
Popma JJ; Satler LF
J Invasive Cardiol; 1994; 6 Suppl A():19A-28A; discussion 45A-50A. PubMed ID: 10155090
[TBL] [Abstract][Full Text] [Related]
8. Laboratory monitoring of heparin and the combination of heparin and the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3) in patients undergoing percutaneous transluminal coronary angioplasty (PTCA).
Zahn R; Haubelt H; Bechtloff S; Schneider S; Frilling B; Rustige J; Marsalek P; Seidl K; Senges J; Hellstern P
Herz; 2003 Aug; 28(5):445-52. PubMed ID: 12928744
[TBL] [Abstract][Full Text] [Related]
9. Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa.
Turner NA; Moake JL; Kamat SG; Schafer AI; Kleiman NS; Jordan R; McIntire LV
Circulation; 1995 Mar; 91(5):1354-62. PubMed ID: 7867173
[TBL] [Abstract][Full Text] [Related]
10. New antiplatelet agents: platelet GPIIb/IIIa antagonists.
Coller BS; Anderson K; Weisman HF
Thromb Haemost; 1995 Jul; 74(1):302-8. PubMed ID: 8578476
[TBL] [Abstract][Full Text] [Related]
11. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
[TBL] [Abstract][Full Text] [Related]
12. The importance of differentiating ReoPro (c7E3 abciximab) induced thrombocytopenia from heparin-induced thrombocytopenia.
Davidson SJ; Turner N; Clague JR; Oldershaw PJ; Burman JF
Thromb Haemost; 1999 Nov; 82(5):1560-1. PubMed ID: 10595660
[No Abstract] [Full Text] [Related]
13. The anti-GPIIb-IIIa agents: fundamental and clinical aspects.
Coller BS; Anderson KM; Weisman HF
Haemostasis; 1996 Oct; 26 Suppl 4():285-93. PubMed ID: 8979134
[TBL] [Abstract][Full Text] [Related]
14. Platelet function tests and flow cytometry to monitor antiplatelet therapy.
Matzdorff A
Semin Thromb Hemost; 2005; 31(4):393-9. PubMed ID: 16149015
[TBL] [Abstract][Full Text] [Related]
15. Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention.
Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Sabaté M; Jimenez-Quevedo P; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Macaya C
Am J Cardiol; 2006 Jan; 97(1):38-43. PubMed ID: 16377281
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA.
McCabe DJ; Harrison P; Mackie IJ; Sidhu PS; Lawrie AS; Purdy G; Machin SJ; Brown MM
Platelets; 2005 Aug; 16(5):269-80. PubMed ID: 16011977
[TBL] [Abstract][Full Text] [Related]
17. Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention.
Furman MI; Kereiakes DJ; Krueger LA; Mueller MN; Broderick TM; Schneider JF; Howard WL; Fox ML; Barnard MR; Frelinger AL; Michelson AD
Am Heart J; 2003 Feb; 145(2):e6. PubMed ID: 12595861
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.
Tcheng JE; Ellis SG; George BS; Kereiakes DJ; Kleiman NS; Talley JD; Wang AL; Weisman HF; Califf RM; Topol EJ
Circulation; 1994 Oct; 90(4):1757-64. PubMed ID: 7923659
[TBL] [Abstract][Full Text] [Related]
19. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
[TBL] [Abstract][Full Text] [Related]
20. Occupancy of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion.
Quinn MJ; Murphy RT; Dooley M; Foley JB; Fitzgerald DJ
J Pharmacol Exp Ther; 2001 May; 297(2):496-500. PubMed ID: 11303035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
